Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
39.83
+0.35 (+0.89%)
Streaming Delayed Price
Updated: 12:14 PM EDT, Aug 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
June 21, 2024
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.
Via
Benzinga
Exposures
Product Safety
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
June 19, 2024
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors.
Via
MarketBeat
Exposures
Product Safety
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 15, 2024
From
Genentech
Via
Business Wire
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
June 11, 2024
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
Via
Investor's Business Daily
Exposures
Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Via
Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
June 07, 2024
From
Genentech
Via
Business Wire
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
June 06, 2024
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.
Via
Benzinga
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
May 29, 2024
You don't need to buy her picks, but it's worth understanding them.
Via
The Motley Fool
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
May 29, 2024
From
Genentech
Via
Business Wire
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
May 26, 2024
What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised.
Via
The Motley Fool
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
May 23, 2024
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
May 21, 2024
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.
Via
Benzinga
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
May 21, 2024
From
Genentech
Via
Business Wire
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
May 16, 2024
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with...
Via
Benzinga
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
May 16, 2024
From
Genentech
Via
Business Wire
Can Ocugen Stock Keep Churning Higher?
April 29, 2024
This tiny biotech caught fire in 2024. Can it sustain the momentum?
Via
The Motley Fool
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
April 24, 2024
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving...
Via
Benzinga
Exposures
Product Safety
2 Small-Cap Growth Stocks With Room To Run
April 24, 2024
These two small-cap growth stocks could be ready to run.
Via
The Motley Fool
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
April 18, 2024
From
Genentech
Via
Business Wire
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
April 17, 2024
From
Genentech
Via
Business Wire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
April 15, 2024
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.
Via
Benzinga
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
April 15, 2024
From
Genentech
Via
Business Wire
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
April 14, 2024
Think globally with this high-yielding ETF.
Via
The Motley Fool
Topics
ETFs
Why Roche Holdings Stock Popped Today
April 11, 2024
Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.
Via
The Motley Fool
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
April 10, 2024
Recursion is playing the long game with its AI-focused approach to drug discovery and development.
Via
The Motley Fool
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
April 08, 2024
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.